A single dose of dimethyltryptamine (DMT), the potent psychoactive component of ayahuasca, may offer a new pathway to alleviate depression, according to a recent study. Researchers at Imperial College London conducted a phase 2a clinical trial involving 34 participants with long-standing depression.
Participants received either a 21.5 milligram dose of DMT or a placebo, administered intravenously over 10 minutes, alongside psychotherapeutic support. The study found that those treated with DMT exhibited a significantly greater reduction in depressive symptoms compared to the placebo group. These positive effects were observed to persist for up to three months following the trial's commencement.
The research indicated that DMT was well-tolerated, with no serious adverse events reported. Mild to moderate side effects were the most common, primarily injection site pain.
While the findings are encouraging, independent experts emphasize the need for further research to fully assess the treatment's efficacy and safety, particularly concerning potential negative psychological experiences.
This development comes amidst a global need for novel depression treatments, as millions worldwide experience insufficient relief from current therapies like SSRIs. The study authors highlight psychedelics as a promising area for innovation in mental health.